Leukemia has been treated with chemotherapy for the past 40 years with only moderate success. A growing body of evidence suggests that by augmenting the immune system more effective results may be obtained. This is highlighted by T cell reinfusions resulting in durable remissions in patients with chronic myelogenous leukemia who have relapsed after an allogeneic transplant. Interleukin-2 is the primary growth factor for T lymphocytes and is a stimulator of natural killer cell activity. It has now been shown that a limited number of otherwise refractory leukemias can be effectively treated with interleukin-2. However, there remains a lack of correlation between the biologic and clinical effects of interleukin-2. The clinical activity of interleukin-2 appears to be greatest in myeloid leukemias. A variety of dose schedules and routes of administration make it difficult to determine if interleukin-2 given to patients in clinical remission is of benefit. Large randomized studies are necessary to explore the role of interleukin-2 in leukemia.
Introduction
Despite years of intensive research and improved chemotherapy regimens most adult patients diagnosed with leukemia will die from their disease. Recent advances in therapy have been achieved by incorporating approaches that target tumor biology. For example, although rare, acute promyelocytic leukemia is now routinely cured by a combination of chemotherapy and all-trans rentinoic acid; a therapy directed at changes in a cell surface receptor that is part of its pathobiology. 1 Because of the requirement for a histocompatible donor, allogeneic bone marrow transplant remains an option for only a minority of patients with leukemia and is associated with significant morbidity and mortality. Consequently, new, alternative therapeutic approaches are needed that more specifically target leukemic clones.
Immunotherapy represents one such effort. Various observations support the potential utility of this approach. First, a defective immune system often coexists with malignancy. This has been highlighted by the finding of defective T cell receptors in patients with advanced malignancy 2 and defective natural killer cell activity in patients with leukemia. 3 These deficiencies often correct upon achievement of a complete remission. Second, patients who are immunodeficient have a higher propensity to develop both hematologic and solid malignancies. The increased incidence of malignancy in AIDS patients 4 and those of solid organ transplant recipients who receive immunosuppressive drugs substantiate this risk. 5 Third, tumors may express antigens that are either tumor specific, or overexpressed, thus allowing them to be targeted by either antibody or cellular therapy. Recent antibody therapy for lymphomas 6 and breast cancer, 7 and tumor-specific T cell infusions for melanoma 8 have demonstrated evidence of efficacy. These observations suggest that the immune system plays an important role in tumor surveillance and that it can be exploited in the development of therapeutic strategies.
The applicability of immune-based therapy for leukemia is still the subject of ongoing studies. The most prominent success has been with chronic myelogenous leukemia (CML). T cell-depleted allogeneic bone marrow transplant is associated with a high relapse rate in CML compared to non-T celldepleted transplants. 9 T cell reinfusions given to patients with CML who have relapsed after allogeneic transplant result in a durable remission rate of 70%. 10 This is accomplished without additional chemotherapy. The same strategy has been applied to acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM), with modest success. 11 These observations strongly suggest that the immune system can play an important role in the abrogation of leukemic clones and have laid the foundation for studies utilizing interleukin-2 (IL-2) in leukemia.
Interleukin-2 and leukemia
Interleukin-2 is secreted by activated T cells and is critical in the generation of an immune response and production of lymphokine activated killer (LAK) cells. IL-2 promotes the proliferation and cytotoxicity of natural killer cells and may promote the elaboration of other cytokines such as GM-CSF, gamma interferon, and tumor necrosis factor. In clinical studies, IL-2 was capable of inducing clonal T cell responses in patients with a known malignancy. Due to a lack of tumorspecific antigens in most tumors, it remains unknown whether these clonal T cells are tumor specific. 12 Interleukin-2 receptors may well be expressed on acute leukemic cells. However, IL-2 does not appear to induce a proliferative signal on leukemic cells, 13 and in fact may inhibit it. 14 Despite this in vitro work there have been rare cases of acute leukemia treated with IL-2 where relapse was associated with de novo expression of the IL-2 receptor (CD-25) on leukemic blasts. 15 Preclinical studies support a potential role for IL-2 in the treatment of leukemia. Lymphokine activated killer (LAK) cells are derived from incubating peripheral blood mononuclear cells with IL-2. Pre-incubation of myeloblasts in semi-solid medium with normal LAK cells results in a near complete abrogation of leukemic growth. 16, 17 Patients with leukemia who are in complete remission have been shown to have LAK cells that are capable of lysing autologous blasts. 18 In a murine model, normal LAK cells abrogated the in vivo growth of human leukemic cell lines.
19 These laboratory and pre-clinical studies have led to the development of clinical studies in humans.
Clinical trials of interleukin-2 and acute leukemia
Early clinical trials utilizing IL-2 for leukemia were disappointing. 20, 21 Patients with a high percentage of blasts in the marrow rarely achieved responses after treatment with IL-2. Foa et al 22 treated 12 patients with chemotherapy-resistant AML with IL-2. No responses occurred in the seven patients with high bone marrow blast counts (20-70%), but three out of five patients with limited disease (8-15%) obtained a complete remission. This encouraging result for patients who have less than 30% residual blasts in their marrow was substantiated by additional studies. Meloni et al 23 reported a series of 14 patients treated with IL-2 who had 7-24% bone marrow blasts. Eight patients achieved complete remission after therapy with IL-2, and five remain in complete remission after a median follow-up of 32 months. Patients received weekly doses of IL-2 at 8 × 10 6 IU/m 2 /day to 18 × 10 6 IU/m 2 /day by continuous infusion for 5 days for a total of four courses. The dose of IL-2 varied based on individual patient tolerance. Patients received maintenance continuous infusion IL-2 at lesser doses until relapse. The remission of some patients exceeded the length of their previous longest response. A similar study of 13 patients was reported by Lim et al. 24 Patients with AML received two 5 day courses of continuous infusion IL-2 at 18 × 10 6 IU/m 2 /day (3 × 10 6 Cetus units m 2 /day) 2 weeks apart. This was followed by continuous infusion maintenance doses of IL-2 every 4 weeks for 5 days until disease progression. The results were less dramatic, however the responses were limited to those patients with minimal residual blasts in the bone marrow. Five out of 13 patients were alive without disease progression, with the longest follow-up being 16 months. Some of these patients were in clinical remission prior to the initiation of IL-2.
Interleukin-2 and acute leukemia in remission
These clinical data suggest an opportunity for the use for IL-2 when there is minimal residual disease present. Additional observations support the view that IL-2 may be more effective after cytoreductive chemotherapy. First, an endogenous rise in LAK cell activity 25 and CD8 + lymphocytes 26 occurs after the administration of high-dose chemotherapy. T cells from patients who have undergone high-dose chemotherapy produce sub-normal amounts of IL-2 when stimulated with either phytohemagglutin (PHA) or phorbol myristate acetate (PMA). These T cells also fail to proliferate after activation through the antigen receptor-dependent CD3 pathway. 27 Exogenous IL-2 may correct this deficiency and enhance an ongoing immune response. Second, soluble factors in the serum of patients with myeloid leukemia can suppress immune function. 28 Serum from patients with AML can inhibit natural killer cell and lectin-dependent cellular cytotoxicity of normal donor lymphocytes. Reducing myeloblasts with chemotherapy could abrogate this inhibitory effect and allow for a more effective immune response to IL-2. These considerations led to the evaluation of the role of IL-2 as maintenance therapy, either after initial induction therapy or after bone marrow transplant, when a state of minimal residual disease exists.
Cortes et al 29 6 U/m 2 /day for a median of 9 days over a 59 day period. The 3 year disease-free survival rate was 41%. Neither the duration of exposure nor dose of IL-2 correlated with the risk of relapse. There was also no correlation between the biologic effects of IL-2 (LAK or NK cytotoxicity, change in CD56 or CD3 positive lymphocytes) and the risk of relapse. In most of these early studies, IL-2 was begun after there was evidence of engraftment. However, some murine models have suggested that IL-2 might be used more effectively if given immediately post-reinfusion of bone marrow or when the bone marrow is activated ex vivo with IL-2 prior to reinfusion. 35, 36 Klingemann et al 37 reported a study using IL-2 exposed cultured bone marrow of patients with AML in first clinical remission. Bone marrow was cultured for 8 days with IL-2 and reinfused, followed immediately by subcutaneous IL-2 at 2-6 × 10 5 U/m 2 /day. Bone marrow recovery was delayed with absolute neutrophil count Ͼ0.5 × 10 9 /ml not reached until a median of 49 days post-reinfusion. This suggests that IL-2 delayed bone marrow engraftment. Five out of 10 patients remain in CR between 18 and 32 months post-BMT.
There are few randomized studies utilizing IL-2 in acute leukemias. Attal et al 38 reported the results of a study in patients with ALL who received autologous bone marrow transplant after first clinical remission. Patients were randomized to either IL-2 or observation. Continuous infusion IL-2 was given at 12 × 10 6 U/m 2 /day for 5 days every other week for five courses. Patients randomized to IL-2 had a 3 year disease-free survival, which was comparable to those not receiving IL-2. IL-2 did not decrease the high relapse rate observed after autologous bone marrow transplant for patients with ALL. Faber et al 39 reported the results of a multicenter randomized study of patients with AML in first clinical remission after induction chemotherapy which compared 14 patients treated with lowdose IL-2 to 10 patients not treated with IL-2. Patients received subcutaneous IL-2 at 0.2 × 10 6 U/m twice daily for 3 months. This very small study failed to show an effect of IL-2 on overall survival, perhaps because the dose of IL-2 was substantially less than that used in other trials.
Interleukin-2 and chronic myelogenous leukemia
Enthusiasm for immune-based therapy for CML stems from the awareness that potent graft-versus-leukemia effect exists for this disease for patients undergoing allogeneic bone marrow transplant. Many patients with CML who relapse after allogeneic transplantation respond to T cell infusions but there are occasional failures. Those patients have been successfully retreated if IL-2 is given in conjunction with T cell infusions. 40 Five out of six patients with overt hematologic relapse did not respond to T cell infusions but did respond when IL-2 was added. The proportion of patients that responded to this therapy was much higher for those with CML (83%) as opposed to those with acute leukemias (45%). 40 As a result of a 9/22 chromosomal translocation, CML is known to express a fusion protein (bcr/abl) which is capable of being recognized by specific T cells. 41 IL-2 may promote this recognition. Furthermore, IL-2 has been shown to downregulate the production of this fusion protein in CML cell lines. 42 These observations laid the foundation for the use of IL-2 in CML outside of its present transplant setting. Some early studies have had encouraging results. 43, 44 One such study is the subject of a short report in this issue.
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Conclusion
Where do we stand with IL-2 in leukemia? Currently, no study has definitively demonstrated a role for IL-2 in leukemia, but preliminary results in AML and CML are encouraging since dramatic results occasionally occur. IL-2 may be helpful for a select number of patients with leukemia analogous to the use of IL-2 for renal cell cancer. Overall response rates of renal cell cancer to IL-2 remain low (15-25%) with a complete remission rate of 5-10%. 45, 46 Yet the dramatic response in a few patients where all other therapy has failed has established IL-2 as the standard therapy for this disease. Studies using IL-2 for ALL appear less encouraging. 38, 47, 48 The optimal dose and schedule of IL-2 therapy has yet to be determined. Mertens et al 49 was unable to show a correlation between escalating doses of IL-2 and augmentation of immune parameters although others have found that a correlation does exist. 50 Jimenez et al 51 demonstrated that low-dose IL-2 given after autologous bone marrow transplant produced similar immune modulation whether it was given subcutaneously or by continuous intravenous infusion. Moderate doses of IL-2 (1-10 × 10 6 IU/m 2 /day) should probably be included in leukemia studies, as most studies that demonstrated response included similar doses. Moderate doses of IL-2 are needed to stimulate resting T cells although there remains a poor correlation between the clinical effects of IL-2 and its biological effects. Lower doses of IL-2 might be used shortly after chemotherapy is completed while the patient is still cytopenic to take advantage of a favorable environment for immunomodulation. Randomized studies are necessary to determine if IL-2 can decrease the relapse rate in leukemia either after standard induction/consolidation therapy or after bone marrow transplant.
Some studies have suggested that IL-2 used in combination with other agents might be more effective than IL-2 alone in the treatment of leukemia. For example, IL-2 has been combined with histamine in the treatment of AML with surprisingly good results. 52 Another strategy might be to combine IL-2 with interferon alpha since the latter may upregulate the expression of MHC class 2 molecules leading to better tumor recognition. We reported in this issue 53 the results of four patients treated with a combination of IL-2 and chemotherapy who were either in accelerated or blast phase CML. The surprisingly long survival in this small series of patients raises the hope of a more effective therapy for advanced stage CML. Large studies in a multi-institutional setting are necessary to determine if a population of otherwise resistant leukemias such as CML in blast crisis can be effectively treated with IL-2 or a combination of IL-2 and chemotherapy.
